MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT’s lead drug, which outperformed its blockbuster drug, Keytruda, in a lung cancer study.
Biotech · China · Merck&Co (MRK)
XTheStockMarketNews.com is a financial news aggregator for traders and investors that proposes to you the latest breaking news headlines on global financial markets, economy and business. Live trading analysis, opinions and forecasts on current stock market, currencies (Forex), cryptocurrency, commodities futures, ETFs, funds, bonds, rates and more. Disclaimer: by using any material of this website, you acknowledge and agree that TheStockMarketNews.com is not responsible for the content, actions or any legal issues arising from third-party websites; materials of this website are not financial advice or call to actions. Trading and investing in financial instruments involve high risks including the risk of investment loss.
Stock Market News